Skip to main content
ANAPTYSBIO, INC logo

ANAPTYSBIO, INC — Investor Relations & Filings

Ticker · ANAB ISIN · US0327241065 LEI · 529900HH4WQT03IG1A12 US Professional, scientific and technical activities
Open in API
Filings indexed 636 across all filing types
Latest filing 2019-05-07 Interim / Quarterly Rep…
Country US United States of America
Listing US ANAB

About ANAPTYSBIO, INC

https://www.anaptysbio.com/

AnaptysBio, Inc. is a clinical-stage biotechnology company that focuses on the discovery and development of innovative immunology therapeutics. The company specializes in advancing immune cell-modulating antibodies designed to treat autoimmune and inflammatory diseases. Its therapeutic candidates target key pathways in the immune system to address significant unmet medical needs for various patient populations.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2019
2019-05-07 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 7, 2019, reporting the financial results for the quarter ended March 31, 2019. It includes a press release attached as Exhibit 99.01 announcing the financial results. The text explicitly states this is a current report pursuant to the Securities Exchange Act of 1934 and the financial results are for a quarter, indicating it is an earnings release. The document length is 3814 characters, which is relatively short and typical for an earnings release announcement. The content is not a full quarterly report with detailed financial statements but rather a press release announcing results. Therefore, the appropriate classification is Earnings Release (ER).
2019-05-07 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is identified as a Schedule 14A filing, which is a proxy statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is labeled as a 'Definitive Additional Materials' filing related to a proxy statement. Proxy statements are materials sent to shareholders to provide information and request votes for meetings. The document length is short (2100 characters), and it is clearly a proxy solicitation document rather than an annual report, earnings release, or other financial report. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI).
2019-04-26 English
DEF 14A
Proxy Solicitation & Information Statement
2019-04-26 English
FORM 4 SUBMISSION
Director's Dealing
2019-04-19 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by AnaptysBio, Inc. on February 28, 2019. It registers additional shares under the company's 2017 Equity Incentive Plan and Employee Stock Purchase Plan. The document includes details about the registration fee, share amounts, and incorporates by reference prior registration statements. It is a regulatory filing related to securities registration and does not contain financial statements, earnings data, or management discussion. It is not an annual report, earnings release, or any other financial report type. It is a specific SEC filing for registering securities under employee benefit plans, which fits under the category of Regulatory Filings (RNS) as it does not match any other more specific category in the provided list.
2019-02-28 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.